[
    [
        {
            "time": "2018-01-02",
            "original_text": "AbbVie (ABBV) Gains But Lags Market: What You Should Know",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Gains",
                    "Lags",
                    "Market"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Gains But Lags Market: What You Should Know",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Vertex CEO Provided Best Value for Investors",
            "features": {
                "keywords": [
                    "Vertex",
                    "CEO",
                    "Value",
                    "Investors"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Vertex CEO Provided Best Value for Investors",
                "Correlation": 8,
                "Sentiment": 9,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication",
            "features": {
                "keywords": [
                    "Merck",
                    "Antibiotic",
                    "Recarbrio",
                    "FDA",
                    "Nod",
                    "Indication"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Merck's Antibiotic Recarbrio Gets FDA Nod for New Indication",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "AbbVie (ABBV) Joins Race for Developing Coronavirus Treatment",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Race",
                    "Coronavirus",
                    "Treatment"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie (ABBV) Joins Race for Developing Coronavirus Treatment",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "Silgan, Canada Goose, Sempra Energy, Fortinet and Abbvie highlighted as Zacks Bull and Bear of the Day",
            "features": {
                "keywords": [
                    "Silgan",
                    "Canada Goose",
                    "Sempra Energy",
                    "Fortinet",
                    "Abbvie",
                    "Zacks",
                    "Bull",
                    "Bear"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "diverse sectors"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Silgan, Canada Goose, Sempra Energy, Fortinet and Abbvie highlighted as Zacks Bull and Bear of the Day",
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 7,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-01-02",
            "original_text": "AbbVie’s Rinvoq Beats Bristol-Myers’ Orencia In New Rheumatoid Arthritis Data",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Rinvoq",
                    "Bristol-Myers",
                    "Orencia",
                    "Rheumatoid",
                    "Arthritis",
                    "Data"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AbbVie’s Rinvoq Beats Bristol-Myers’ Orencia In New Rheumatoid Arthritis Data",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        }
    ]
]